What the FDA labels say about taking them together
Aripiprazole lauroxil and carbamazepine
Aripiprazole lauroxil's FDA label of January 28, 2025 names carbamazepine in its drug interactions section; carbamazepine's label does not name aripiprazole lauroxil itself but warns about its class (Atypical antipsychotics). The aripiprazole lauroxil label: “Concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of oral aripiprazole alone.”
Check it at the source: the aripiprazole lauroxil FDA label on DailyMed (effective January 28, 2025, Alkermes, Inc.); the carbamazepine FDA label on DailyMed (effective August 20, 2026, Novartis Pharmaceuticals Corporation).
What does the aripiprazole lauroxil label say about carbamazepine?
Aripiprazole lauroxil label, drug interactionsStrong CYP3A4 Inducers Clinical Impact: The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of oral aripiprazole alone. Intervention: With concomitant use of ARISTADA with a strong CYP3A4 inducer for more than 2 weeks consider increasing the ARISTADA dose [see Dosage and Administration ()]. Examples: carbamazepine, rifampin
Aristada Initio label (Alkermes, Inc., January 28, 2025), drug interactionsStrong CYP3A4 Inducers Clinical Impact: Concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of oral aripiprazole alone. Intervention: Avoid concomitant use of ARISTADA INITIO with strong CYP3A4 inducers because the dosage of ARISTADA INITIO cannot be modified [see Dosage and Administration ()]. Examples: carbamazepine, rifampin
Source: FDA drug label (Aristada Initio, NDA209830), Alkermes, Inc., effective January 28, 2025 (SPL set b18fdfd9-31cd-4a2f-9f1c-ebc70d7a9403), via openFDA
Source: FDA drug label (ARISTADA), Alkermes, Inc., effective January 28, 2025 (SPL set 17a8d11b-73b0-4833-a0b4-cf1ef85edefb), via openFDA; the full label on DailyMed
What does the carbamazepine label say about aripiprazole lauroxil?
Carbamazepine's label does not name aripiprazole lauroxil itself; it warns about its class (Atypical antipsychotics):
Carbamazepine label, drug interactionsCNS Depressants The concomitant use of Carbatrol and other CNS depressants can increase the risk of respiratory depression, profound sedation, hypotension, and syncope. CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants.
Source: FDA drug label (Tegretol), Novartis Pharmaceuticals Corporation, effective August 20, 2026 (SPL set 8d409411-aa9f-4f3a-a52c-fbcb0c3ec053), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aripiprazole lauroxil | Carbamazepine | |
|---|---|---|
| Labeled for | Schizophrenia | Bipolar disorder, Seizures and epilepsy |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $993.60 per mL 1,064 mg/3.9 mL syringe | $0.119 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once